Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Abide Therapeutics Announces Collaboration with Merck

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
Collaboration agreement to develop novel therapies for type 2 diabetes and metabolic diseases.

Abide Therapeutics has announced that it has entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

"This collaboration leverages Abide's unique and innovative therapeutic engine," said Alan Ezekowitz, MBChB, D.Phil., President and CEO of Abide Therapeutics.

Ezekowitz continued, "We are eager to validate unique targets that we hope will lead to the development of novel therapeutics that will benefit patients with diabetes and metabolic diseases."

Under the terms of the agreement, Abide Therapeutics is eligible to receive an upfront payment, research funding, and potential milestone payments for up to $430 million for three products.

Further details of the financial terms were not disclosed. Merck will have worldwide commercialization rights to any products that may be developed as a result of the collaboration.

Abide Therapeutics is entitled to receive royalty payments on global sales from any such products.

"Diabetes and related disorders continue to represent a significant global, unmet medical need," said Nancy Thornberry, Senior Vice President and Franchise Head, Diabetes and Metabolism, Merck Research Laboratories.

Thornberry continued, "We look forward to working with Abide on the discovery and development of important new medicines."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
Newly Identified Biochemical Pathway Could Be Target for Insulin Control
Researchers at Duke Medicine and the University of Alberta are reporting the identification of a new biochemical pathway to control insulin secretion from islet beta cells in the pancreas, establishing a potential target for insulin control.
Dirty,Crusty Meals Fit for (Long-Dormant) Microbes
Researchers apply the latest analytical techniques to further our understanding of desert biocrusts.
CSI -- On The Metabolite's Trail
Bioinformaticians at the University of Jena make the most efficient search engine for molecular structures available online.
Developing a Breathalyzer-Type Low Blood Sugar Warning Device For Diabetes
A multidisciplinary team of researchers at Indiana University-Purdue University Indianapolis has been awarded a $738,000 National Science Foundation grant to develop a breathalyzer-type device to detect the onset of hypoglycemia, or low blood sugar episodes, in people with diabetes.
Identifying The 'Dimmer Switch' Of Diabetes
University of Alberta research gives new insight into what causes Type 2 diabetes.
10 to 1: Bugs Win in NASA study
Bugs are winning out, and that's a good thing according to NASA's Human Research Program.
MYC Oncogene Disrupts Cancers Rhythm
Findings inform time-dependent treatment for reducing side effects and increasing effectiveness of cancer medications.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos